Unum Therapeutics Inc. (UMRX)

[swanlinbar]

UMRX-Unum Therapeutics Inc (NASDAQ:UMRX) Receives Consensus Recommendation of “Buy” from Analysts
Posted by ABMN Staff on May 28th, 2020 // No Comments

Unum Therapeutics logoUnum Therapeutics Inc (NASDAQ:UMRX) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.88.

Several equities research analysts have recently weighed in on the stock. Morgan Stanley downgraded shares of Unum Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 3rd. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Friday, March 6th. Wedbush reissued a “hold” rating and issued a $1.00 target price on shares of Unum Therapeutics in a research report on Sunday, March 29th. Finally, HC Wainwright dropped their target price on shares of Unum Therapeutics from $18.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, March 27th.